Potential of dihydropyrimidine dehydrogenase genotypes in personalizing 5-fluorouracil therapy among colorectal cancer patients

Potential of dihydropyrimidine dehydrogenase genotypes in personalizing 5-fluorouracil therapy among colorectal cancer patients

Show other versions (1)

BACKGROUND:: Dihydropyrimidine dehydrogenase (DPD) is a pyrimidine catabolic enzyme involved in the initial and rate-limiting step of the catabolic pathway of toxic metabolites of 5-fluorouracil (5-FU). Several studies have reported that deficiency of DPD and polymorphisms of its gene are related to...

Full description

Bibliographic Details
Main Authors: Bannur, Z. (Author), Fijeraid, H. (Author), Hamzah, S. (Author), Hasbullani, Z. (Author), Hashim, H. (Author), Md Nor, A. (Author), Ngow, H. (Author), Ramasamy, P. (Author), Salleh, M.Z (Author), Shia, J.K.S (Author), Sood, S. (Author), Teh, L.K (Author), Zailani, M. (Author), Zakaria, Z.A (Author)
Format: Article
Language:English
Subjects:
5-fluorouracil
adult
adverse effect
aged
anemia
Antimetabolites, Antineoplastic
article
cancer chemotherapy
chemotherapy induced emesis
clinical article
colorectal cancer
Colorectal Neoplasms
coughing
denaturing high performance liquid chromatography
diarrhea
dihydropyrimidine dehydrogenase
Dihydrouracil Dehydrogenase (NADP)
drug blood level
drug fever
Drug-Related Side Effects and Adverse Reactions
enzyme activity
female
fluorouracil
Fluorouracil
gastrointestinal toxicity
genetic polymorphism
genetic variability
genotype
Genotype
hand paresthesia
hand tremor
hematoma
hematuria
high performance liquid chromatography
human
Humans
leukocyte count
leukopenia
loss of appetite
male
nausea
neutropenia
personalized medicine
pharmacogenotypes
polymerase chain reaction
Polymorphism, Genetic
predictive value
priority journal
quantitative assay
side effect
upper respiratory tract infection
weight reduction
Online Access:View Fulltext in Publisher
View in Scopus

Internet

View Fulltext in Publisher
View in Scopus

Similar Items